Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dorine Fournier"'
Autor:
Alexandre Brudon, Dorine Fournier, Frédéric Selle, Emmanuel Seront, Rosa Conforti, Gwenaëlle Veyrac, Aurore Gouraud, Bénédicte Lebrun-Vignes, Antoine Khalil, Gérard Zalcman, Valérie Gounant
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background PARP inhibitors (PARPi) are used in the treatment of ovarian, breast, pancreatic, and prostate cancers. Pneumonitis has been identified as a potential side effect, with a higher meta-analysis-assessed risk for olaparib versus othe
Externí odkaz:
https://doaj.org/article/50324750c659418484b2a66070fd6bcc
Autor:
Laurent Chouchana, Dorine Fournier, Bénédicte Lebrun-Vignes, Sophie Florence, Laura I. Levi, Caroline Charlier, Claire Foirest
Publikováno v:
Journal of Infection. 86:256-308
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d24945de280174c0d96a6e2df4430b2c
https://doi.org/10.1016/j.jinf.2023.01.005
https://doi.org/10.1016/j.jinf.2023.01.005
Autor:
Lina Jeantin, Adèle Hesters, Dorine Fournier, Bénédicte Lebrun-Vignes, Aurélie Méneret, Caroline Papeix, Valérie Touitou, Elisabeth Maillart
Publikováno v:
Journal of Neurology. 269:5647-5650
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5ccc7a594f122c5759041902a5365f8
https://doi.org/10.1007/s00415-022-11130-x
https://doi.org/10.1007/s00415-022-11130-x
Autor:
Astrid Prioul, Dorine Fournier, Cécile Lefeuvre, Sophie Duranton, Pascale Olivier, Emeline Blanc, Laure Peyro-Saint-Paul, Sophie Ruault, Aurélie Jamet, Catherine Mouchel
Publikováno v:
Therapies
Therapies, 2023, ⟨10.1016/j.therap.2023.02.008⟩
Therapies, 2023, ⟨10.1016/j.therap.2023.02.008⟩
International audience; INTRODUCTION: The evaluation of clinical trial (CT) safety is the main task of CT vigilance units. In addition to the management of adverse events, the units must review the literature to identify information that may impact t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6568de4cae838104db9ebc336171e312
https://hal.science/hal-04061230/document
https://hal.science/hal-04061230/document
Autor:
Dorine Fournier, Stéphane Jouneau, Guillaume Bouzillé, Elisabeth Polard, Marie-Noëlle Osmont, Lucie-Marie Scailteux
Publikováno v:
Pulmonary Pharmacology and Therapeutics
Pulmonary Pharmacology and Therapeutics, 2022, 76, pp.102149. ⟨10.1016/j.pupt.2022.102149⟩
Annual Meeting of French Society of Pharmacology and Therapeutics
Annual Meeting of French Society of Pharmacology and Therapeutics, Jun 2022, Lille, France. 36, pp.77-78, 2022
Pulmonary Pharmacology and Therapeutics, 2022, 76, pp.102149. ⟨10.1016/j.pupt.2022.102149⟩
Annual Meeting of French Society of Pharmacology and Therapeutics
Annual Meeting of French Society of Pharmacology and Therapeutics, Jun 2022, Lille, France. 36, pp.77-78, 2022
Introduction: While pirfenidone and nintedanib have greatly influenced the treatment of idiopathic pulmonary fibrosis (IPF), both drugs have significant early adverse drug reactions (ADRs) and almost nothing is known of their rare and delayed ADRs. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f463e5ba0ebf3d17710bd8bdd4015b
https://univ-rennes.hal.science/hal-03954444/document
https://univ-rennes.hal.science/hal-03954444/document
Publikováno v:
Archives of Cardiovascular Diseases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb59a3976f08b39bd230dde3da23f75
https://doi.org/10.1016/j.acvd.2021.09.001
https://doi.org/10.1016/j.acvd.2021.09.001